^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) + cyclophosphamide (Alkylating agent) + epirubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Published date:
11/17/2021
Excerpt:
HR+/HER2- BC patients, however, had significantly better 4-year iDFS (77.9% iddEPC versus 62.5% PM, HR = 2.11 [95%CI 1.08-4.10], log-rank p = 0.025) and 4-year OS with iddEPC (94.7% iddEPC versus 80.1% PM, HR = 3.26 [95%CI 1.06-10.00], log-rank p = 0.029)....While there was no difference in survival for the entire cohort, the HR+/HER2-subgroup significantly benefits from iddEPC.
DOI:
10.1016/j.ejca.2021.10.011
Trial ID:
